Topiramate’s effectiveness on weight reduction in overweight/obese persons with schizophrenia: study protocol for a randomized controlled trial
Abstract Background Schizophrenia is a psychiatric disorder with a higher mortality than that of the general population. Most of the deaths are due to cardiovascular causes and are related to metabolic risks. This risk is due not only to antipsychotics but also to inherent factors of the disorder. S...
Main Authors: | Miyuru Chandradasa, Layani Champika, Silumini de Silva, K. A. L. A. Kuruppuarachchi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2017-09-01
|
Series: | Trials |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13063-017-2162-6 |
Similar Items
-
Clozapine induced severe weight loss in resistant schizophrenia managed with risperidone add-on therapy
by: M. Chandradasa, et al.
Published: (2020-12-01) -
Metabolic side effects of antipsychotic drugs in individuals with schizophrenia during medium- to long-term treatment: protocol for a systematic review and network meta-analysis of randomized controlled trials
by: Johannes Schneider-Thoma, et al.
Published: (2021-08-01) -
C677T Polymorphism in the MTHFR Gene Is Associated With Risperidone-Induced Weight Gain in Schizophrenia
by: Jingping Liao, et al.
Published: (2020-07-01) -
Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
by: Jing Huang, et al.
Published: (2020-05-01) -
Corrigendum: Increased Appetite Plays a Key Role in Olanzapine-Induced Weight Gain in First-Episode Schizophrenia Patients
by: Jing Huang, et al.
Published: (2020-06-01)